DSM Panel Members Still Getting Pharma Funds
Despite promises to cut back on Pharma funds, 56% of DSM V panel members have reported industry ties— Zero improvement over the percent of DSM-IV members.
Despite promises to cut back on Pharma funds, 56% of DSM V panel members have reported industry ties— Zero improvement over the percent of DSM-IV members.
As psychiatrists from around the world flood the area this weekend to take part in the Annual Meeting of the American Psychiatric Association (APA), psychiatric watchdog Citizens Commission on Human Rights (CCHR) is demanding that the APA sever all ties to pharmaceutical company interests and that psychiatrists stop killing children with harmful drugs.
Critics say there’s a damaging conflict of interest with the financial ties between drug companies and experts who are revising the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), as well as guidelines on the best treatments. This question has been a big topic of debate not just in scientific and academic journals it also concerns the public welfare.
The American Psychiatric Association yesterday gave the press an advance view of its proposed Diagnostic and Statistical Manual of Mental Disorders, and the reports were highly skeptical. Will Tiger Woods soon be diagnosed with “hypersexual disorder”? He could be if the proposals go into effect. The APA will be accepting comments through April. The news reports barely noted the fact that dozens of psychiatrists who serve on the DSM-V (it’s the fifth edition) task force and working groups have financial ties to the pharmaceutical and medical device industries.